| | Identification | Back Directory |  | [Name] 
 ALPHA-(4-CHLOROPHENYL)-4-[(4-FLUOROPHENYL)METHYL]-1-PIPERIDINEETHANOL
 |  | [CAS] 
 119431-25-3
 |  | [Synonyms] 
 SL 820715
 ELIPRODIL
 1-(4-broMophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanol
 α-(4-Chlorophenyl)-4-[(4-fluorophenyl)Methyl]-1-piperidineethanol
 1-(4-chlorophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethan-1-ol
 α-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol
 (+-)-alpha-(p-Chlorophenyl)-4-(p-fluorobenzyl)-1-piperidineethanol
 1-Piperidineethanol, α-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-
 ALPHA-(4-CHLOROPHENYL)-4-[(4-FLUOROPHENYL)METHYL]-1-PIPERIDINEETHANOL
 SL  820715,  α-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol
 |  | [Molecular Formula] 
 C20H23ClFNO
 |  | [MDL Number] 
 MFCD00866651
 |  | [MOL File] 
 119431-25-3.mol
 |  | [Molecular Weight] 
 347.85
 | 
 | Chemical Properties | Back Directory |  | [Boiling point ] 
 474.1±35.0 °C(Predicted)
 |  | [density ] 
 1.205±0.06 g/cm3(Predicted)
 |  | [storage temp. ] 
 2-8°C
 
 |  | [solubility ] 
 DMSO: ~17 mg/mL
 
 |  | [form ] 
 solid
 
 |  | [pka] 
 13.99±0.20(Predicted)
 |  | [color ] 
 white
 
 | 
 | Hazard Information | Back Directory |  | [Description] 
 N-Methyl-D-aspartate (NMDA) receptors are calcium permeable ligand-gated channels of the central nervous system that are activated after binding of the co-agonists glutamate and glycine. Eliprodil is a non-competitive NMDA receptor antagonist that inhibits neuronal calcium channel currents. It is selective for NR2B subunit-containing receptors (IC50 = 1 μM), displaying greater than 100-fold selectivity for NR2B over NR2A and NR2C subunits. Eliprodil also avidly binds σ1 and σ2 sites (Kis = 0.013 and 0.63 μM, respectively). It is effective in vivo, blocking ischemia-induced neurodegeneration in the CA1 region of the hippocampus of gerbils subjected to bilateral carotid artery occlusion. Eliprodil can also have proarrhythmic actions in hearts under normal conditions.
 |  | [Uses] 
 Eliprodil is a noncardiac drug with neuroprotective properties. It is also a N-Methyl-D-aspartate receptor (NMDAR) antagonist.
 |  | [Definition] 
 ChEBI: Eliprodil is a racemate comprising equimolar amounts of (R)- and (S)-eliprodil. It is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-ischaemic agent that exhibits neuroprotective properties. It has a role as a geroprotector, a NMDA receptor antagonist, a neuroprotective agent and a calcium channel blocker. It contains a (R)-eliprodil and a (S)-eliprodil.
 |  | [Biological Activity] 
 Non-competitive  NMDA  receptor  antagonist  that  acts  at  the  polyamine  modulatory  site.  Selective  for  NR2B-  over  NR2A-  and  NR2C-containing  receptors  (IC  50 values  are  1,  >  100  and  >  100 μ  M  respectively).  Also σ 1 ligand  (K  i =  0.013 μ  M).  Antagonizes  neuronal  voltage-gated  Ca  2+ channels  and  selectively  inhibits  the  rapid  component  of  the  delayed  rectifier  K  + current  (I  Kr  ).  Neuroprotective.
 |  | [storage] 
 +4°C (desiccate)
 |  | [References] 
 [1] CATHERINE P. BATH. The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia[J]. European journal of pharmacology, 1996, 299 1: Pages 103-112. DOI: 10.1016/0014-2999(95)00846-2
 [2] E R WHITTEMORE   R M W  V I Ilyin. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.[J]. Journal of Pharmacology and Experimental Therapeutics, 1997, 282 1: 326-338.
 [3] SARAH GRIMWOOD. Characterisation of N-Methyl-D-Aspartate Receptor-Specific [3H]Ifenprodil Binding to Recombinant Human NR1a/NR2B Receptors Compared with Native Receptors in Rodent Brain Membranes[J]. Journal of Neurochemistry, 2008, 75 6: 2455-2463. DOI: 10.1046/j.1471-4159.2000.0752455.x
 [4] CSABA LENGYEL. Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic risk[J]. British Journal of Pharmacology, 2009, 143 1: 152-158. DOI: 10.1038/sj.bjp.0705901
 | 
 |  |